Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical (LFCR) Gross Profit: 2009-2025

Historic Gross Profit for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $14.0 million.

  • Lifecore Biomedical's Gross Profit fell 19.05% to $14.0 million in Q2 2025 from the same period last year, while for May 2025 it was $40.3 million, marking a year-over-year decrease of 3.71%. This contributed to the annual value of $40.3 million for FY2025, which is 3.71% down from last year.
  • Lifecore Biomedical's Gross Profit amounted to $14.0 million in Q2 2025, which was up 42.02% from $9.8 million recorded in Q1 2025.
  • Lifecore Biomedical's Gross Profit's 5-year high stood at $17.3 million during Q2 2024, with a 5-year trough of $2.7 million in Q3 2023.
  • Moreover, its 3-year median value for Gross Profit was $9.9 million (2023), whereas its average is $9.8 million.
  • As far as peak fluctuations go, Lifecore Biomedical's Gross Profit plummeted by 54.37% in 2023, and later soared by 122.03% in 2024.
  • Lifecore Biomedical's Gross Profit (Quarterly) stood at $11.5 million in 2021, then slumped by 50.44% to $5.7 million in 2022, then soared by 75.33% to $10.0 million in 2023, then increased by 11.32% to $11.1 million in 2024, then declined by 19.05% to $14.0 million in 2025.
  • Its Gross Profit stands at $14.0 million for Q2 2025, versus $9.8 million for Q1 2025 and $11.1 million for Q4 2024.